a developer of pharmaceutical drugs for treating cancer and inflammatory diseases
Industry Biotechnology
A.I.dvisor tells us that CASI and RIGL have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CASI and RIGL's prices will move in lockstep.
Ticker / NAME | Correlation To CASI | 1D Price Change % | ||
---|---|---|---|---|
CASI | 100% | +5.95% | ||
RIGL - CASI | 30% Poorly correlated | +0.18% | ||
VICP - CASI | 29% Poorly correlated | N/A | ||
ATRA - CASI | 26% Poorly correlated | -10.45% | ||
ONCO - CASI | 25% Poorly correlated | -6.32% | ||
OPORF - CASI | 23% Poorly correlated | N/A | ||
More |
Ticker / NAME | Correlation To CASI | 1D Price Change % |
---|---|---|
CASI | 100% | +5.95% |
cancer theme (82 stocks) | 19% Poorly correlated | -2.35% |
inflammation theme (11 stocks) | 19% Poorly correlated | -2.42% |
biotechnology theme (238 stocks) | 16% Poorly correlated | -1.76% |
pharmaceuticals theme (159 stocks) | 15% Poorly correlated | -1.90% |
drugs theme (254 stocks) | 13% Poorly correlated | -1.67% |